EdiGene snags about $67m Series B

Beijing-based EdiGene, Inc., a developer of genome editing technologies, has raised about $67 million in Series B financing.

13 October 2020•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles